Clinical trial
The Epigenetic Modification of Somatostatin Receptor-2 to Improve Therapeutic Outcome With Lutathera in Patients With Metastatic Neuroendocrine Tumours.
NCT05178693 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Epigenetic Modification of Somatostatin Receptor-2 to Improve Therapeutic Outcome With Lutathera in Patients With Metastatic Neuroendocrine Tumours.
- Lead sponsor
- Imperial College London
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 25, 2022
- Completion date
- February 28, 2029
- Enrollment
- 27 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.